We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Molecular Diagnostics Market Worth Nearly USD 7 Billion

By LabMedica International staff writers
Posted on 21 Feb 2017
Print article
The size of the molecular diagnostic testing market has reached USD 6.7 billion and is being driven by the growing threat of infectious disease and cancer, as well as the development of new products. These are the latest findings of Kalorama Information, an independent medical market research firm.

The main technologies for clinical molecular diagnostics comprise nucleic acid amplification tests (NAATs) based on real-time PCR (qPCR) and other amplification-detection protocols; direct nucleic acid probe tests such as in situ hybridization (ISH) and its fluorescent ISH (FISH); next-generation sequencing (NGS); amplification followed by probe-based hybridization on arrays (or microarrays); and other related methods.

According to Kalorama, nucleic acid amplification tests and sequencing-based tests will be the future of the molecular diagnostics market. Meanwhile, qPCR and next-generation sequencing will be the preferred choice for cancer testing and prenatal screening due to their superior sensitivity and non-invasive sampling. Competitive displacement is expected in cytogenetics, new cancer tests and blood culture tests, though in situ hybridization will retain application markets in cancer testing with a share of 47% of the total molecular diagnostics market for cancer in 2021.

Over the next five years, infectious disease is expected to account for 60% of the global molecular diagnostics. Time to results for real-time PCR and isothermal amplification remain vital for various infectious disease testing applications, such as respiratory testing, hospital-acquired infections, bloodstream infections, and molecular point-of-care tests.

The molecular infectious disease diagnostics segment is defined by test decentralization with the introduction of NAAT platforms, which can be operated in hospital laboratories, and near-patient points of care, such as physician office labs and outpatient clinics. Larger clinical laboratories find integrated design from sample preparation to results analysis and user friendly features equally appealing as it frees up personnel.

Players in the molecular infectious disease diagnostics segment have been focusing on expanding the menu on integrated analyzers. However, their market share and client retention will depend on the ability to perform all routine infectious disease tests on a single platform.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.